AD Pharma

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Industry Development Trend and Key Manufacturers Analysis 2017-2022 : Global QYResearch

Press Release   •   Feb 23, 2017 11:30 EET

This report studies sales (consumption) of United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market 2017, focuses on the top players, with sales, price, revenue and market share for each player, covering

Conatus Pharmaceuticals
Daewoong Pharmaceutical
Galmed International
Kyorin Pharmaceutical
Metabolic Solutions Development
Novartis AG
Phenex Pharmaceuticals
Raptor Pharmaceuticals
TCM Biotech International
Tobira Therapeutics
Verva Pharmaceuticals
Zafgen

Market Segment by States, covering
California
Texas
New York
Florida
Illinois

Request more information at http://globalqyresearch.com/download-sample/174156 

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Type I
Type II

Split by applications, this report focuses on sales, market share and growth rate of Non-alcoholic Fatty Liver Disease (NAFLD) Drug in each application, can be divided into
Application 1
Application 2

View full report at http://globalqyresearch.com/united-states-non-alcoholic-fatty-liver-disease-nafld-drug-market-report-2017

Table of Contents

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Report 2017
1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Overview
1.1 Product Overview and Scope of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.2 Classification of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.2.1 Type I
1.2.2 Type II
1.3 Application of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.3.1 Application 1
1.3.2 Application 2
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Non-alcoholic Fatty Liver Disease (NAFLD) Drug (2012-2022)
1.4.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2022)
1.4.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2022)

2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Competition by Manufacturers
2.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price by Manufactures (2015 and 2016)
2.4 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competitive Situation and Trends
2.4.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Concentration Rate
2.4.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion

3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales (Volume) and Revenue (Value) by States (2012-2017)
3.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by States (2012-2017)
3.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by States (2012-2017)
3.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by States (2012-2017)

4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales (Volume) and Revenue (Value) by Type (2012-2017)
4.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type (2012-2017)
4.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)
4.4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Type (2012-2017)

5 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales (Volume) by Application (2012-2017)
5.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application (2012-2017)
5.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturers Profiles/Analysis
6.1 Conatus Pharmaceuticals
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Daewoong Pharmaceutical
6.2.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Galmed International
6.3.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Kyorin Pharmaceutical
6.4.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Metabolic Solutions Development
6.5.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Novartis AG
6.6.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Phenex Pharmaceuticals
6.7.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Raptor Pharmaceuticals
6.8.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 TCM Biotech International
6.9.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Tobira Therapeutics
6.10.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Verva Pharmaceuticals
6.12 Zafgen

7 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturing Cost Analysis
7.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Forecast (2017-2022)
11.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue Forecast (2017-2022)
11.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Forecast by Type (2017-2022)
11.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Forecast by Application (2017-2022)
11.4 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price Forecast (2017-2022)

12 Research Findings and Conclusion

13 Appendix

To Purchase this premium Report With Complete TOC at http://globalqyresearch.com/checkout-form/0/174156

About Us:

Global QYResearch (http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact Us:

Unit1, 26 Cleveland Road, South Woodford, London, E182AN, United Kingdom

Contact: +44 20 32392407

Email: sales@globalqyresearch.com

Follow us:https://www.linkedin.com/company/global-qy-research

Twitter: https://twitter.com/gqyresearch